Abbott Laboratories Stock News

Abbott Laboratories (NYSE:ABT ) Q3 2025 Earnings Call October 15, 2025 9:00 AM EDT Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President & CEO Philip Boudreau - CFO & Executive VP of Finance Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Resea...

CCLA Investment Management disclosed a purchase of 66,275 shares of Abbott Laboratories (ABT -3.20%) , estimated at ~$8.70 million based on the quarterly average price, in its SEC filing for the period ended September 30, 2025, filed on October 14, 2025.

Abbott Laboratories (NYSE:ABT) reported steady growth in the third quarter, with sales rising 6.9% to $11.37 billion, slightly below estimates of $11.4 billion, and adjusted earnings per share matching expectations at $1.30. The company's results were driven by broad-based strength across Abbott's medical devices and diagnostics businesses, even as COVID-19 testing-related revenue continued to ...

There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn't leave investors at the mercy of short-term and often irrational market sentiment, limits fees and taxes, and (especially when dividends are reinvested) puts the magic of compounding to work.

Abbott stock skidded early Wednesday after the health giant reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales.

The company narrowed its guidance for the second time this year.

Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults

Abbott reported higher quarterly revenue on Wednesday, driven by strong demand for its medical devices including continuous glucose monitors and heart devices.